SLC5A2 and type 2 diabetes mellitus: This notion is emphasized by recent evidence demonstrating that Dapagliflozin, an anti‐T2DM and sodium–glucose co‐transporter‐2 (SGLT2) inhibitor medication, is reported to decrease ultra‐rapid outward potassium current (IKur), IKr, and late sodium current (INa) and increase inwardly rectifying potassium current (IK1) (Müller et al. 2024; Philippaert et al. 2021), in addition to alleviating diabetic retinopathy by abrogating the cPLA2 phosphorylation by MAPK, thereby reducing AA (Hu et al. 2022).